Phase II clinical trial of Genexol® (paclitaxel) and carboplatin for patients with advanced non-small cell lung cancer

Cancer Research and Treatment

Volumn 43, Issue 1, 2011, Pages 19-23

  Kim, Han Jo ^a   Kim, Kyoung Ha ^a   Yun, Jina ^b   Kim, Se Hyung ^b   Kim, Hyun Jung ^b   Lee, Sang Cheol ^a   Bae, Sang Byung ^a   Kim, Chan Kyu ^b   Lee, Nam Su ^a   Lee, Kyu Taek ^a   Kim, Do Jin ^b   Park, Seong Kyu ^b   Won, Jong Ho ^a   Hong, Dae Sik ^b   Park, Hee Sook ^a  

^a Soonchunhyang University   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Carboplatin; Chemotherapy; Genexol; Non small cell lung carcinoma

Indexed keywords

EID: 84857441780     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2011.43.1.19     Document Type: Article

References (10)

1. Ministry for Health, Welfare and Family Affairs, Headquarters of Central Cancer Registry. 2007 Annual report of the Korea Cancer Registration. Seoul: Ministry for Health, Welfare and Family Affairs; 2009.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-8.
3. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210-8.
4. Lee SH, Park K, Suh C, Kim HK, Kim JS, Im YH, et al. A multi-center, phase II clinical trial of Genexol® (paclitaxel) and cisplatin for patients with non-small cell lung cancer. Cancer Res Treat. 2003;35:30-4.
5. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.
6. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, et al. Threearm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer. A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group: EORTC 08975. J Clin Oncol. 2003;21:3909-17.
7. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51.
8. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2000;11:799-805.
9. Morère JF, Piperno-Neumann S, Coulon MA, Vaylet F, L'Her P, Brunet A, et al. Dosefinding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. Anticancer Drugs. 2000;11:541-8.
10. Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dosesequencing study in patients with non-small-cell lung cancer: the European Cancer Centre. J Clin Oncol. 1997;15:317-29.